Idenix Pharmaceuticals to present at the BMO Capital Markets 2008 Focus on Healthcare Conference Idenix to Host Conference Call Discussing Second Quarter 2008 Financial Results Positive Phase I/II Data of IDX899 Confirm Potent Antiviral Activity and Favorable Safety Profile in Treatment-Naive HIV-Infected Patients

Second Quarter 2008 Financial Results July 29, 2008 XVII International AIDS Conference August 3-8, 2008 BMO Capital Markets Focus on Healthcare Conference August 5-6, 2008   XVII International Drug Resistance Workshop Materials